Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker. 1988

J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
Albert Einstein College of Medicine, New York, New York.

The hemodynamic effects of flestolol were evaluated in 30 patients undergoing routine cardiac catheterization. Hemodynamic measurements were obtained during baseline (prior to flestolol), at steady state during IV flestolol infusion (1, 5, and 10 micrograms/kg/min) and at 20 to 30 minutes after discontinuation (postinfusion). Flestolol-induced hemodynamic changes were similar to those induced by other beta blockers without intrinsic sympathomimetic activity. Significant dose-dependent reduction in heart rate, rate pressure product, and increase in peripheral vascular resistance were seen. Flestolol produced clinically insignificant decrease in myocardial contractility as shown by slight decrease in LVdp/dt, CI, and LVEF. Hemodynamic data from patients with paced heart rate, further confirms a direct mild cardiac depressant effect of flestolol, a finding common to other beta blockers. Consistent with the short elimination half-life of flestolol (t1/2 = 6.5 minutes), most of the hemodynamic changes rapidly returned to preinfusion level within 20 to 30 minutes following its discontinuation. Thus flestolol, with its unique pharmacokinetic profile and titrability, may be beneficial in the treatment of critically ill patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011412 Propanolamines AMINO ALCOHOLS containing the propanolamine (NH2CH2CHOHCH2) group and its derivatives. Aminopropanols
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005464 Fluorobenzenes Derivatives of BENZENE that contain FLUORINE. Fluorobenzene
D006352 Heart Ventricles The lower right and left chambers of the heart. The right ventricle pumps venous BLOOD into the LUNGS and the left ventricle pumps oxygenated blood into the systemic arterial circulation. Cardiac Ventricle,Cardiac Ventricles,Heart Ventricle,Left Ventricle,Right Ventricle,Left Ventricles,Right Ventricles,Ventricle, Cardiac,Ventricle, Heart,Ventricle, Left,Ventricle, Right,Ventricles, Cardiac,Ventricles, Heart,Ventricles, Left,Ventricles, Right
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
May 1986, Clinical pharmacology and therapeutics,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
January 1987, Journal of clinical pharmacology,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
October 1987, American heart journal,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
January 1986, American heart journal,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
March 1986, Journal of clinical pharmacology,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
January 1987, Journal of cardiovascular pharmacology,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
March 1988, International journal of clinical pharmacology, therapy, and toxicology,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
April 1986, Journal of pharmaceutical sciences,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
August 1987, Journal of clinical pharmacology,
J Strom, and M Josephson, and W H Frishman, and B Singh, and S Heilbrunn, and S Osterle, and P Turlapaty, and R Viray, and J Coe, and V Bell
June 1987, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!